Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 1
1(33.3%)
N/A
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06902194Recruiting

To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children

Role: lead

NCT05590325Phase 1Unknown

Pharmacokinetics and Safety of DolutegravIr in Neonate

Role: lead

NCT01900977Not ApplicableCompleted

Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART)

Role: collaborator

NCT02391415Phase 2Completed

Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa

Role: collaborator

All 4 trials loaded